

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number  
WO 03/009740 A3

(51) International Patent Classification<sup>7</sup>:  
5/02, A61K 39/395, 39/00, 35/26, 35/28

C12N 5/00,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/21631

(22) International Filing Date: 10 July 2002 (10.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/307,688 24 July 2001 (24.07.2001) US  
60/382,459 22 May 2002 (22.05.2002) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): BIO-GEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

Published:

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): VAISHNAW, Akshay, K. [GB/US]; 25 Draper Avenue, Arlington, MA 02474 (US).

(74) Agent: MYERS, Louis; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).

(88) Date of publication of the international search report:

11 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/009740 A3

(54) Title: METHODS FOR TREATING OR PREVENTING SCLEROTIC DISORDERS USING CD2-BINDING AGENTS

(57) Abstract: Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US02/21631

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 5/00, 02; A61K 39/395, 00; A61K 35/26, 28  
US CL : 435/41, 325, 375; 424/130.1, 143.1, 184.1, 577

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 435/41, 325, 375; 424/130.1, 143.1, 184.1, 577

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,547,853 A (WALLNER et al) 20 August 1996 (20.08.1996), see entire document, SEQ ID 12 in particular.	1-105
X	US 6,162,432 A (WALLNER et al) 19 December 2000 (19.12.2000), see entire document, SEQ ID NO:12 in particular.	1-105

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
	Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 20 February 2003 (20.02.2003)	Date of mailing of the international search report 20 JUN 2003
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <i>Alicia D. Roberts for</i> Michail A Belyavskyi Telephone No. 703/308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/21631

Continuation of B. FIELDS SEARCHED Item 3:  
BIOSIS, CAPLUS, SCISearch, Medline, Embase, WEST, uspatfull, PCTfull,  
search terms: Vaishnav, A; CD2, LFA-3, binding agent, SEQ ID NO:2, T cell, fibrotic disorder.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :  C12P 21/00, C12N 5/00, 1/00		A1	(11) International Publication Number: <b>WO 88/ 09820</b>  (43) International Publication Date: 15 December 1988 (15.12.88)
--	--	----	---

(21) International Application Number: PCT/US88/01924  (22) International Filing Date: 3 June 1988 (03.06.88)  (31) Priority Application Number: 057,615  (32) Priority Date: 3 June 1987 (03.06.87)  (33) Priority Country: US  (71) Applicants (for all designated States except US): BIOGEN N.V. [NL/NL]; Pietermaai 15, Willemstad, Curaçao (AN). DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US).  (71)(72) Applicants and Inventors: WALLNER, Barbara, P. [US/US]; 7 Centre Street, Cambridge, MA 02139 (US). SPRINGER, Timothy, A. [US/US]; 28 Monadnock Road, Newton, MA 02167 (US). HESSION, Catherine [US/US]; 96 Fountain Lane, #6, South Weymouth, MA 02190 (US). TIZARD, Richard [US/US]; 334 Harvard Street, No. D-3, Cambridge, MA 02139 (US). MATTALIANO, Robert [US/US];	114 East Side Parkway, Newton, MA 02158 (US). DUSTIN, Michael, L. [US/US]; 231 Park Drive, Apt. 23, Boston, MA 02215 (US).  (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 875 Third Avenue, New York, NY 10022-6250 (US).  (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), HU, IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.
---	---

Published

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3

(57) Abstract

Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides bind to CD2 on the surface of T-lymphocytes and inhibit adhesion between T-lymphocytes and target cells. DNA sequences that code on expression in appropriate unicellular hosts for those polypeptides. Methods of making and using those polypeptides in therapy and diagnosis.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

DNA SEQUENCES, RECOMBINANT DNA MOLECULES  
AND PROCESSES FOR PRODUCING LYMPHOCYTE  
FUNCTION ASSOCIATED ANTIGEN-3

5        This invention relates to DNA sequences, recombinant DNA molecules and processes for producing Lymphocyte Function Associated Antigen-3 (LFA-3). More particularly, the invention relates to DNA sequences that are characterized in that they code 10      on expression in an appropriate unicellular host for LFA-3 or derivatives thereof that bind to CD2, the receptor on the surface of T-lymphocytes. More preferably, the LFA-3 of this invention and its derivatives bind to CD2 on the surface of T-lymphocytes. 15      Most preferably, they also inhibit adhesion between T-lymphocytes and target cells. In accordance with this invention, unicellular hosts transformed with these DNA sequences and recombinant DNA molecules containing them may also be employed to produce LFA-3 20      essentially free of other proteins of human origin. This novel antigen may then be used in the therapeutic and diagnostic compositions and methods of this invention.

BACKGROUND OF THE INVENTION

25        T-lymphocytes play a major role in the immune response by interacting with target and antigen presenting cells. For example, the T-lymphocyte mediated killing of target cells is a multi-step

process involving adhesion of a cytolytic T-lymphocyte to a target cell. And, helper T-lymphocytes initiate the immune response by adhesion to antigen-presenting cells.

5           These interactions of T-lymphocytes with target and antigen-presenting cells are highly specific and depend on the recognition of an antigen on the target or antigen-presenting cell by one of the many specific antigen receptors on the surface 10          of the T-lymphocyte.

15          The receptor-antigen interaction of T-lymphocytes and other cells is also facilitated by various T-lymphocyte surface proteins, e.g., the antigen receptor complex CD3(T3) and accessory molecules CD4, LFA-1, CD8, and CD2. It is also dependent on accessory molecules, such as LFA-3, ICAM-1 and MHC that are expressed on the surface of the target or antigen-presenting cells. In fact, it is hypothesized that the accessory molecules on the T-lymphocytes and on the target or antigen-presenting cells interact with each other to mediate intercellular adhesion. Accordingly, these accessory molecules are thought to enhance the efficiency of lymphocyte-antigen-presenting cell and lymphocyte-target cell interactions and to be important in leukocyte-endothelial cell interactions and lymphocyte recirculation.

20          For example, recent studies have suggested that there is a specific interaction between CD2 (a T-lymphocyte accessory molecule) and LFA-3 (a target cell accessory molecule) that mediates T-lymphocyte adhesion to the target cell. This adhesion is essential to the initiation of the T-lymphocyte functional response (M. L. Dustin et al., "Purified Lymphocyte 25          Function-Associated Antigen-3 Binds To CD2 And Mediates T Lymphocyte Adhesion, J. Exp. Med., 165, pp. 677-92 (1987); Springer et al., Ann. Rev. Immunol.

(1987) (in press)). And, monoclonal antibodies to either LFA-3 or CD2 have been shown to inhibit a spectrum of cytolytic T lymphocyte and helper T lymphocyte dependent responses (F. Sanchez-Madrid et al., "Three Distinct Antigens Associated With Human T-Lymphocyte-Mediated Cytolysis: LFA-1, LFA-2, And LFA-3", Proc. Natl. Acad. Sci. USA, 79, pp. 7489-93 (1982)).

10 LFA-3 is found on antigen-presenting cells, and target cells, specifically on monocytes, granulocytes, CTL's, B-lymphoblastoid cells, smooth muscle cells, vascular endothelial cells, and fibroblasts (Springer et al., supra).

15 Human LFA-3 has been purified from human erythrocytes (Dustin et al., supra). It is a glycoprotein of 60,000 to 70,000 molecular weight, having a sugar content of about 50%. This purified LFA-3 binds to CD2 on the surface of T-lymphocytes and inhibits adhesion between T-lymphocytes and erythrocytes (Dustin et al., supra).

20 25 However, for ultimate use in therapy and diagnosis larger amounts of less costly LFA-3 are required than would be available from purification from erythrocytes. Moreover, for therapeutic use it would be more preferable to obtain LFA-3 from a source other than human erythrocytes, which may be contaminated with viruses, such as hepatitis B viruses or AIDS viruses.

#### SUMMARY OF THE INVENTION

30 35 This invention solves these problems. It provides in large amounts LFA-3 and derivatives that bind to CD2, the receptor on the surface of T-lymphocytes. More preferably, the LFA-3 of this invention and its derivatives bind to CD2 on the surface of T-lymphocytes and they also inhibit adhesion between T-lymphocytes and target cells. More particularly,

this invention relates to soluble forms of LFA-3. It also provides LFA-3 essentially free of other proteins of human origin and in a form that is not contaminated by viruses, such as AIDS or hepatitis B.

5 This invention accomplishes these goals by providing DNA sequences coding on expression in an appropriate unicellular host for LFA-3 or those derivatives thereof. Moreover, this invention provides DNA sequences that are characterized in that 10 they code on expression for soluble forms of LFA-3.

15 This invention also provides recombinant DNA molecules containing those DNA sequences and unicellular hosts transformed with them. Those hosts permit the production of large quantities of the novel LFA-3 and derivatives of this invention for use in a wide variety of therapeutic and diagnostic compositions and methods.

The DNA sequences of this invention are selected from the group consisting of:

20 (a) the DNA sequence: the DNA insert carried in phage λHT16;

(b) DNA sequences which hybridize under conditions equivalent to about 20° to 27°C below T<sub>m</sub> to the aforementioned DNA sequence and that code on expression for polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes; and

25 (c) DNA sequences which code on expression for a polypeptide coded for on expression by any of the foregoing DNA sequences.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the amino acid sequences of the N-terminal and various peptide fragments of human LFA-3, purified from human erythrocytes using 35 immunoaffinity chromatography.

Figure 2 depicts two pools of chemically synthesized oligonucleotide DNA probes derived from the amino acid sequence of human LFA-3 purified from human erythrocytes.

5           Figure 3 depicts the DNA sequence of the DNA insert carried in phage  $\lambda$ HT16. Figure 3 also depicts the nucleotide sequence of a cDNA sequence coding on expression for human LFA-3 and the amino acid sequence deduced therefrom.

10           Figure 4 depicts the relevant portions of sequencing plasmid pNN01.

Figure 5 depicts the nucleotide sequence of probes LF-10, LF-11, NN-A, NN-B, NN-C, and NN-D.

DETAILED DESCRIPTION OF THE INVENTION

15           We isolated the DNA sequences of this invention from two libraries: a  $\lambda$ gt10 cDNA library derived from peripheral blood lymphocytes from leuko-phoresis #9 and a  $\lambda$ gt10 cDNA library derived from human tonsil. However, we could also have employed 20 libraries prepared from other cells that express LFA-3. These include, for example, monocytes, granulocytes, CTL's, B-lymphoblastoid cells, smooth muscle cells, vascular endothelial cells and fibroblasts. We also could have used a human genomic bank.

25           For screening these libraries, we used a series of chemically synthesized anti-sense oligonucleotide DNA probes. We selected these probes from a consideration of the amino acid sequences of various fragments of LFA-3 that we determined using 30 LFA-3 purified from human erythrocytes. These fragments are depicted in Figure 1. We selected amino acids from various areas of LFA-3 that permitted the construction of oligonucleotide probes of minimal degeneracy.

35           We prepared two pools of probes: LF1 and LF2-5. These pools are depicted in Figure 2. LF1

is a 32-fold degenerate 20-mer and LF2-5 is a 384-fold degenerate 20-mer. Because of the high degeneracy of this latter pool, we subdivided the pool into four subpools -- LF2, LF3, LF4 and LF5 -- of 96-fold degeneracy each.

For screening, we hybridized our oligo-nucleotide probes to our cDNA libraries utilizing a plaque hybridization screening assay. We selected clones hybridizing to several of our probes. And, after isolating and subcloning the cDNA inserts of the selected clones into plasmids, we determined their nucleotide sequences and compared the amino acid sequences deduced from those nucleotide sequences to the amino acid sequences that we had determined previously from our purified human LFA-3. As a result of these comparisons, we determined that all of our selected clones were characterized by cDNA inserts coding for amino acid sequences of human LFA-3.

We have depicted in Figure 3 the nucleotide sequence of the longest of these cDNA inserts (the DNA insert of phage  $\lambda$ HT16) and the DNA sequence coding for LFA-3 and the amino acid sequence deduced therefrom. As shown in Figure 3, this cDNA insert has an open reading frame of 750 bp (250 amino acids), a 16 bp 5' untranslated region and a 201 bp 3' untranslated region. A comparison of the deduced amino acid sequence of Figure 3 with the N-terminal amino acid sequence that we determined from LFA-3 purified from human erythrocytes suggests that amino acids -28 to -1 comprise a signal sequence and that amino acids 1 to 222 comprise the protein sequence of mature LFA-3.

The cDNA sequence depicted in Figure 3 and contained in deposited clone  $\lambda$ HT16 may be used in a variety of ways in accordance with this invention. It, portions of it, or synthetic or semi-synthetic copies of them, may be used as DNA probes to screen other human or animal cDNA or genomic libraries to

select by hybridization other DNA sequences that are related to LFA-3. Typically, conventional hybridization conditions, e.g., about 20° to 27°C below Tm are employed in such selections. However, less stringent 5 conditions may be necessary when the library is being screened with a probe from a different species than the library, e.g., the screening of a mouse library with a human probe.

10 The cDNA sequence of Figure 3, portions of it, or synthetic or semi-synthetic copies of them, may also be used as starting materials to prepare various mutations. Such mutations may be either degenerate, i.e., the mutation does not change the amino acid sequence encoded for by the mutated codon, 15 or non-degenerate, i.e., the mutation changes the amino acid sequence encoded for by the mutated codon. Both types of mutations may be advantageous in producing or using LFA-3's of this invention. For example, these mutations may permit higher levels of 20 production, easier purification or higher LFA-3 activity.

For all of these reasons, the DNA sequences of this invention are selected from the group consisting of:

25 (a) the DNA sequence: the DNA insert carried in phage  $\lambda$ HT16;

(b) DNA sequences which hybridize under conditions equivalent to about 20° to 27°C below Tm to the aforementioned DNA sequence and which code 30 on expression for a polypeptide that binds to CD2, the receptor on the surface of T-lymphocytes; and

(c) DNA sequences which code on expression for a polypeptide coded for on expression by any of the foregoing DNA sequences.

35 Preferably, the DNA sequences of this invention code for a polypeptide having the sequence depicted for amino acids 1 to 222 of Figure 3 (with

or without an additional N-terminal methionine) or portions thereof. More preferably, the DNA sequence for this invention will be modified as compared to that of Figure 3 (amino acids 1 to 222) in order to 5 remove from it those portions that code for the hydrophobic transmembrane portion, e.g., from about nucleotide 662 to 715, to allow production of a smaller protein. Most preferably, the DNA sequences of this invention code for soluble proteins or pep- 10 tides that bind to CD2, the receptor on the surface of T-lymphocytes. More preferably, the LFA-3 and derivatives of this invention bind to CD2 on the surface of T-lymphocytes. Most preferably, they 15 also inhibit adhesion between T-lymphocytes and target cells.

The DNA sequences of this invention are also useful for producing the LFA-3 or its derivatives coded on expression by them in unicellular hosts transformed with those DNA sequences. As well known 20 in the art, for expression of the DNA sequences of this invention the DNA sequence should be operatively linked to an expression control sequence in an appropriate expression vector and employed in that expression vector to transform an appropriate unicellular 25 host.

Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes the provision of a translation start signal in the correct reading frame upstream 30 of the DNA sequence. If the particular DNA sequence of this invention being expressed does not begin with a methionine, e.g., mature LFA-3 which begins with a phenylalanine, the start signal will result in an additional amino acid -- methionine -- being 35 located at the N-terminus of the product. While such methionyl-containing-product may be employed directly in the compositions and methods of this

invention, it is usually more desirable to remove the methionine before use. Methods are available in the art to remove such N-terminal methionines from polypeptides expressed with them. For example, 5 certain hosts and fermentation conditions permit removal of substantially all of the N-terminal methionine in vivo. Other hosts require in vitro removal of the N-terminal methionine. However, such in vivo and in vitro methods are well known in the 10 art.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of 15 chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from E.coli including col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, e.g., RP4, 20 phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM989, and other DNA phages, e.g., M13 and Filamentous single stranded DNA phages, yeast plasmids such as the  $2\mu$  plasmid or derivatives thereof, and vectors derived from combinations of plasmids 25 and phage DNAs, such as plasmids which have been modified to employ phage DNA or other expression control sequences. For animal cell expression, we prefer to use plasmid BG312, a plasmid containing the major late promoter of adenovirus 2.

30 In addition, any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence when operatively linked to it -- may be used in these vectors to express the DNA sequence of this invention. Such 35 useful expression control sequences, include, for example, the early and late promoters of SV40 or the adenovirus, the lac system, the trp system, the TAC

or TRC system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, 5 e.g., Pho5, the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. For animal cell expression, we prefer to 10 use an expression control sequence derived from the major late promoter of adenovirus 2.

A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known 15 eukaryotic and prokaryotic hosts, such as strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi, such as yeasts, and animal cells, such as CHO and mouse cells, African green monkey cells, such as COS1, COS7, BSC1, BSC40, and BMT10, and human cells 20 and plant cells in tissue culture. For animal cell expression, we prefer mouse L-cells.

It should of course be understood that not all vectors and expression control sequences will function equally well to express the DNA sequences 25 of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences, and hosts without undue experimentation and without 30 departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must replicate in it. The vector's copy number, the ability to control 35 that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.

In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence, of this invention, particularly as regards potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded on expression by the DNA sequences of this invention to them, their secretion characteristics, their ability to fold proteins correctly, their fermentation requirements, and the ease of purification of the products coded on expression by the DNA sequences of this invention.

Within these parameters one of skill in the art may select various vector/expression control system/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture, e.g., mouse L cells.

The polypeptides produced on expression of the DNA sequences of this invention may be isolated from the fermentation or animal cell cultures and purified in a variety of ways well known in the art. Such isolation and purification techniques depend on a variety of factors, such as how the product is produced, whether or not it is soluble or insoluble, and whether or not it is secreted from the cell or must be isolated by breaking the cell. One of skill in the art, however, may select the most appropriate isolation and purification techniques without departing from the scope of this invention.

The polypeptides produced on expression of the DNA sequences of this invention, e.g., met-LFA-3 (amino acids 1-222 of Figure 3) or LFA-3 (amino acids 1-222 of Figure 3), the preferred smaller less hydrophobic derivatives thereof, or the more preferred

soluble derivatives thereof, are essentially free of other proteins of human origin and are not contaminated by viruses, such as hepatitis B virus and AIDS. Thus, they are different than LFA-3 purified from 5 human erythrocytes.

These polypeptides are useful in compositions and methods to block or to augment the immune response. For example, the polypeptides of this invention are active in inhibiting cytolytic 10 T-lymphocyte activity by interfering with their interaction with target cells. They have a similar effect on the immune response because they interfere with the interaction of helper T-cells and antigen-presenting cells. Furthermore, the compounds of 15 this invention may be used to target specific T cells for lysis and immune suppression or to deliver drugs, such as lymphokines, to the specifically targeted T-cells. More preferably, soluble derivatives of the polypeptides of this invention may be employed 20 to saturate the CD2 sites of T-lymphocytes thus inhibiting T-cell activation. This effect is plainly of great utility in graft-vs-host disease, in autoimmune diseases, e.g., rheumatoid arthritis, and in preventing allograft rejection. Furthermore, the 25 polypeptides of this invention are preferred over monoclonal antibodies to LFA-3 or CD2 because the polypeptides of this invention are less likely to elicit immune responses in humans than are antibodies raised in species other than humans. The therapeutic 30 compositions of this invention typically comprise an immunosuppressant or enhancement effective amount of such polypeptide and a pharmaceutically acceptable carrier. The therapeutic methods of this invention comprise the steps of treating patients in a pharmaceutically acceptable manner with those compositions. 35

The compositions of this invention for use in these therapies may be in a variety of forms.

These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, suppositories, injectable and infusible solutions. The 5 preferred form depends on the intended mode of administration and therapeutic application. The compositions also preferably include conventional pharmaceutically acceptable carriers and adjuvants which are known to those of skill in the art.

10 Preferably, the compositions of the invention are in the form of a unit dose and will usually be administered to the patient one or more times a day.

Generally, the pharmaceutical compositions of the present invention may be formulated and administered using methods and compositions similar to 15 those used for other pharmaceutically important polypeptides (e.g., alpha-interferon). Thus, the polypeptides may be stored in lyophilized form, reconstituted with sterile water just prior to administration, and administered by the usual routes of 20 administration such as parenteral, subcutaneous, intravenous or intralesional routes.

The polypeptides of this invention or antibodies against them are also useful in diagnostic 25 compositions and methods to detect T-cell subsets or CD2+ cells or to monitor the course of diseases characterized by excess or depleted T-cells, such as autoimmune diseases, graft versus host diseases and allograft rejection.

30 Finally, the polypeptides of this invention or antibodies against them are useful in separating B and T cells. For example, when bound to a solid support the polypeptides of this invention or antibodies to them will separate B and T cells.

35 In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only,

and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLES

Purification and Sequencing of Human LFA-3:

5           We purified the human LFA-3 that we employed to generate tryptic fragments and to determine the partial amino acid sequences depicted in Figure 1 from outdated human erythrocytes (obtained from American Red Cross, Needham, Massachusetts) using a  
10          modification to procedure of Dustin et al., supra. For completeness that modified purification procedure is described below.

15          We purified monoclonal antibody (MAb) TS2/9 (Sanchez-Madrid et al., supra) from hybridoma culture supernatants by  $(\text{NH}_4)_2\text{SO}_4$  precipitation and protein A affinity chromatography. We then used this purified MAb to prepare affinity columns for use in the following purification.

20          We coupled purified MAb to Sepharose CL-4B by a modification of the method of Cuatrecasas (March et al., Anal. Biochem., 60, p. 149 (1974)). We activated washed Sepharose CL-4B (Pharmacia, Upsala, Sweden) with 40 mg/ml CNBr in 1 M  $\text{Na}_2\text{CO}_3$  for 10 min on ice and then washed it with distilled water and 0.1 mM HCl. We filtered the activated Sepharose to a moist cake and added it to the purified antibody solution with 2-4 mg/ml IgG (LFA-3 MAb or mouse IgG) in 0.05 M NaCl and 0.1 M  $\text{NaHCO}_3$  (pH 8.4). We then mixed the suspension end over end for 20 h and then 25          blocked any remaining reactive groups by addition of ethanolamine to 50 mM and incubation for 1 h. We checked the supernatant for uncoupled antibody by measuring absorbance at 280 nm. Coupling was usually 30          on the order of 90%. We then poured the MAb-coupled Sepharose into a column and washed it with one cycle  
35

of pH 11 and pH 3 buffers (see below) before use for affinity chromatography.

5 We purified the LFA-3 after solubilization with Triton X-100 by affinity chromatography as previously described (Dustin et al., supra). We performed all steps at 4°C.

We obtained outdated human erythrocytes from the American Red Cross (Needham, Massachusetts). We washed cells from 2 units of whole blood 3 times 10 with PBS (pH 7.2). We then pelleted the packed cells to about 500 ml and added another 500 ml of PBS (pH 7.2) with 2% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 mM iodoacetamide and 0.2 trypsin inhibitor units/ml aprotinin to the red cell suspension while 15 stirring. After 1 h we centrifuged the lysate at 150,000g for 2 h. We then passed the cleared lysate over two columns in series at a flow rate of 20 ml/h: (1) a mouse IgG-Sepharose column (2 ml at 2 mg/ml) to absorb some contaminants and to filter out any 20 particulate material, and (2) an LFA-3 MAbs-Sepharose column (5-10 ml at 2 mg/ml). We washed the LFA-3 MAbs-Sepharose column with 5 column volumes of 50 mM sodium phosphate (pH 7.2), 0.25 M NaCl, 0.1% Triton X-100, then 5 column volumes of 20 mM triethylamine 25 (pH 11), 0.25 M NaCl, 0.1% Triton X-100 and again with 2 column volumes of the pH 7.2 buffer, all at a flow rate of 1 ml/min. We then eluted the remaining bound LFA-3 with 5 column volumes of 50 mM glycine HCl (pH 3), 0.25 M NaCl, 0.1% Triton X-100 at a flow 30 rate of 20 ml/h. We neutralized the eluted LFA-3 by collecting into 0.1 volume of 1M Tris-HCl (pH 8.6), 0.1% Triton X-100.

When we used octyl- $\beta$ -D-glucopyranoside (OG) (Calbiochem) to elute LFA-3, all steps were the same 35 until after the high pH wash. At that point we washed the column with 5 volumes of phosphate buffer (pH 7.2), 0.15 M NaCl, containing 1% OG, and eluted the

LFA-3 using glycine buffer (pH 3), 0.15 M NaCl, 1% OG. The elution profile was similar to that obtained with Triton X-100. We followed our LFA-3 purification in a semiquantitative manner using a "dot blot" assay (Hawkes et al., Anal. Biochem., 119, p. 142 (1982) with  $^{125}$ -LFA-3 MAb.

To prepare the purified LFA-3 for trypsin digestion and amino acid sequencing, we deglycosylated it using N-glycosidase F, according to the supplier's instructions with minor modifications (Genzyme, Boston Massachusetts). We first separated the LFA-3 from the detergent by ethanol precipitation (Triton X-100) or ultrafiltration (OG). We then denatured the LFA-3 (1 nmol) by boiling with 25  $\mu$ l of 0.5% SDS, 0.2 M 2-mercaptoethanol for 5 min. We next treated the denatured LFA-3 with 5 U/nmole N-glycanase in 50 mM Tris-HCl (pH 8.6) with 3% Triton X-100 and 10 mM 1,10-phenanthroline for 20 h at 37°C in a final volume of 50  $\mu$ l and precipitated the deglycosylated LFA-3 (NG-LFA-3) in ethanol (5 vol. 100% ethanol overnight at -20°C).

We prepared highly purified N-glycanase treated LFA-3 (25 kd) by preparative SDS-PAGE and electroelution. We reduced N-glycanase-treated LFA-3 (approximately 350 pmoles) with 5mM DTT in 250 mM n-ethylmorpholine acetate, 1 mM EDTA, 0.2% SDS (pH 8.25) under argon for 5 min at 100°C, and alkylated it with 11 mM sodium iodoacetate for 30 min at 23°C in the dark. We desalted the product (CM-NG-LFA-3) by gel filtration on Sephadex G-25 M equilibrated with 0.2% SDS, 250 mM N-ethylmorpholinoacetate (pH 8.25) and lyophilized it. We then dispersed the lyophilized LM-NG-LFA-3 in 10 ml absolute ethanol, stored at -20°C for 7 days, and recovered the LFA-3 by centrifugation at 6000  $\times$  g for 30 min at 4°C. We dissolved the pellet in 400  $\mu$ l of 0.1 M  $\text{NH}_4\text{HCO}_3$  and digested it with TPCK-trypsin (15% w/w) as described

in Pepinsky et al., JBC, 261, p. 4239 (1986). We acidified the digest with formic acid to a final concentration of 20% formic acid and immediately fractionated the fragments by reverse phase high pressure liquid chromatography on a narrow bore C<sub>8</sub> column (Aquapore RP300, 0.21 x 10 cm; Brownlee Fabs). We eluted the resulting peptides with a gradient of acetonitrile (0-75%) in 0.1% trifluoroacetic acid at a flow rate of 0.3 ml/min (0.5 min fractions being collected). We monitored the column eluates at both 214 and 280 nm.

We subjected each of intact LFA-3 (300 pMoles), NG LFA-3 (50 pMoles) and tryptic fragments of CM-NG LFA-3 (5-50 pMoles) to automated Edman degradation using an Applied Biosystems 470A gas phase sequencer in the presence of polybrene (Hewick et al., JBC, 256, p. 7990 (1981)). We identified PTH-amino acids on-line using an Applied Biosystems 120A PTH analyzer. Sequencing of the intact protein yielded a sequence of 38 amino acids as shown in Figure 1. Four tryptic fragments, T<sub>72-73</sub>, T<sub>91</sub>, T<sub>105</sub>, and T<sub>68</sub> yielded the other DNA sequences, which are shown in Figure 1.

#### Synthesis of Oligonucleotide Probes

We chemically synthesized two pools of anti-sense oligonucleotide DNA probes coding for regions from the amino terminal sequence of LFA-3 characterized by minimal nucleic acid degeneracy (see underscoring in Figure 1) on an Applied Biosystems 30A DNA synthesizer. For each selected amino acid sequence, we synthesized pools of probes complementary to all possible codons. We synthesized the probes anti-sense to enable hybridization of them to the corresponding sequences in DNA as well as in mRNA. We labelled our oligonucleotide probes using

[ $\gamma$ -<sup>32</sup>P]-ATP and polynucleotide kinase (Maxam and Gilbert, Proc. Natl. Acad. Sci., 74, p. 560 (1977)).

As depicted in Figure 2, the oligonucleotide probe pool LF1 was a 20-mer with 32-fold degeneracy. Probe pool LF2-5, was a 20-mer with 384-fold degeneracy. However, to reduce its degeneracy, we synthesized this pool in four subpools of 96-fold degeneracy each by splitting the degenerate codon for Gly into one of its four possible nucleotides for each subpool. We then selected the subpool containing the correct sequence from the three pools containing incorrect sequences by hybridization of the individual subpools to Northern blots containing human tonsil mRNA, as described previously (Wallner et al., Nature, 320, pp. 77-81 (1986)). Oligonucleotide probe subpool LF2 hybridized to a 1300 nucleotide transcript in human tonsil RNA, which suggested that it contained the correct sequence. Hence, we used it and pool LF1 for screening our various libraries.

20 Construction of  $\lambda$ gt10 Peripheral Blood Lymphocytes cDNA Library

To prepare our Peripheral Blood Lymphocytes (PBL) DNA library, we processed PBL from leukophoresis #9 through one round of absorption to remove monocytes. We then stimulated the non-adherent cells with IFN- $\gamma$  1000 U/ml and 10  $\mu$ g/ml PHA for 24 h. We isolated RNA from these cells using phenol extraction (Maniatis et al., Molecular Cloning, p. 187 (Cold Spring Harbor Laboratory) (1982)) and prepared poly A<sup>+</sup> mRNA by one round of oligo dT cellulose chromatography. We ethanol precipitated the RNA, dried it in a speed vac and resuspended the RNA in 10  $\mu$ l H<sub>2</sub>O (0.5  $\mu$ g/ $\mu$ l). We treated the RNA for 10 min at room temperature in CH<sub>3</sub>HgOH (5mM final concentration) and  $\beta$ -mercaptoethanol (0.26 M). We then added the methyl mercury treated RNA to 0.1 M Tris-HCl (pH 8.3) at 43°C, 0.01 M Mg, 0.01 M DTT, 2 mM Vanadyl complex,

5 µg oligo dT<sub>12-18</sub>, 20 mM KCl, 1 mM dCTP, dGTP, dTTP, 0.5 mM dATP, 2 µCi[ $\alpha$ -<sup>32</sup>P]dATP and 30 U 1.5 µl AMV reverse transcriptase (Seikagaku America) in a total volume of 50 µl. We incubated the mixture for 3 min 5 at room temperature and 3 h at 44°C after which time we stopped the reaction by the addition of 2.5 µl of 0.5 M EDTA.

We extracted the reaction mixture with an equal volume of phenol:chloroform (1:1) and precipitated the aqueous layer two times with 0.2 volume of 10 M NH<sub>4</sub>AC and 2.5 volumes EtOH and dried it under 10 vacuum. The yield of cDNA was 1.5 µg.

We synthesized the second strand according to the methods of Okayama and Berg (Mol. Cell. Biol., 15 2, p. 161 (1982)) and Gubler and Hoffman (Gene, 25, p. 263 (1983)), except that we used the DNA polymerase I large fragment in the synthesis.

We blunt ended the double-stranded cDNA by resuspending the DNA in 80 µl TA buffer (0.033 M Tris 20 Acetate (pH 7.8); 0.066 M KAcetate; 0.01M MgAcetate; 0.001M DTT; 50 µg/ml BSA), 5 µg RNase A, 4 units RNase H, 50 µM  $\beta$  NAD<sup>+</sup>, 8 units E.coli ligase, 0.3125 mM dATP, dCTP, dGTP, and dTTP, 12 units T<sub>4</sub> polymerase and incubated the reaction mixture for 90 min at 25 37°C, added 1/20 volume of 0.5M EDTA, and extracted with phenol:chloroform. We chromatographed the aqueous layer on a G150 Sephadex column in 0.01M Tris-HCl (pH 7.5), 0.1 M NaCl, 0.001 M EDTA and collected the lead peak containing the double-stranded 30 cDNA and ethanol precipitated it. Yield: 605 µg cDNA.

We ligated the double-stranded cDNA to linker 35/36

5' AATTCGAGCTCGAGCGCGGCCGC3'

3' GCTCGAGCTCGCGCCGGCG5'

35 using standard procedures. We then size selected the cDNA for 800 bp and longer fragments on a S500 Sephacryl column, and ligated it to EcoRI digested

λgt10. We packaged aliquots of the ligation reaction in Gigapak (Strategene) according to the manufacturer's protocol. We used the packaged phage to infect E.coli BNN102 cells and plated the cells for amplification. The resulting library contained 5  $1.125 \times 10^6$  independent recombinants.

#### Screening of the Libraries

We screened human tonsil λgt10 cDNA library (Wong et al., Proc. Natl. Acad. Sci., 82, p. 7711-7715 10 (1985)) and the PBL cDNA library prepared above with our labelled oligonucleotide probe LF1 using the plaque hybridization screening technique of Benton and Davis (Science, 196, p. 180 (1977)).

We pelleted an overnight culture of BNN102 15 cells in L broth and 0.2% maltose and resuspended it in an equal volume of SM buffer (50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgSO<sub>4</sub>, and 0.01% gelatin). Thereafter, we preabsorbed 9 ml of cells with 20  $1.5 \times 10^6$  phage particles at room temperature for 15 min and plated them on 30 LB Mg plates.

After incubation at 37°C for 8 h, we lifted the filters from the plates and lysed them by placing them onto a pool of 0.5 N NaOH/1.5 M NaCl for 5 min, and then submerged them for 5 min in the same buffer. 25 We neutralized the filters by submerging them in 0.5 M Tris-HCl (pH 7.4), 1.5 M NaCl, two times for 5 min each, and rinsed them for 2 min in 1 M NH<sub>4</sub>OAc, air dried the filters, and baked them for 2 h at 80°C.

We prehybridized and hybridized the filters 30 to oligonucleotide probe LF1 in 0.2% polyvinylpyrrolidone, 0.2% ficoll (MW 400,000), 0.2% bovine serum albumin, 0.05 M Tris-HCl (pH 7.5), 1 M sodium chloride, 0.1% sodium pyrophosphate, 1% SDS, 10% dextran sulfate (MW 500,000) and 100 µg/ml tRNA. We

detected the hybridizing  $\lambda$ -cDNA sequences by autoradiography.

We initially selected 26 positive phages from the PBL library and 12 positive phages from the 5 tonsil library. We then rescreened these clones and plaque purified them at lower density using the same probe.

We digested isolated DNA from these clones with EcoRI and hybridized them to oligomer probes 10 LF1 and LF2 using the Southern blot technique (E. M. Southern, J. Mol. Biol., 98, pp. 503-18 (1975)). We then further characterized the DNA from two clones 15 of the tonsil library ( $\lambda$ HT16 and  $\lambda$ HT12) and two clones from the PBL library ( $\lambda$ P26 and  $\lambda$ P24) by DNA sequencing analysis.

#### Sequencing of cDNA Clones

We subcloned the EcoRI digested DNA from clones  $\lambda$ HT16 and  $\lambda$ P26 into vector pNN01 to facilitate sequence analysis.\*  $\lambda$ HT16 has 2 EcoRI fragments which 20 we individually subcloned into pNN01 resulting in plasmids pHT16H and pHT16L. The entire insert of  $\lambda$ P26 is contained on a single NotI fragment. For subcloning, we used the vector's EcoRI site or SmaI site employing techniques in common use.

We determined the DNA sequences of our 25 subclones largely by the method of Maxam and Gilbert. (Meth. Enzymology, 1980). However, for some fragments, we used the related procedure of Church and Gilbert (Proc. Natl. Acad. Sci. USA, 81, p. 1991 30 (1984)). The structure of pNN01 enables sequencing,

\* We constructed sequencing plasmid pNN01 by removing the synthetic polylinker of pUC8 by restriction digestion and replacing it with a new synthetic segment. The 2.5 kb backbone common to the pUC plasmids, which provides an origin of replication and confers ampicillin resistance, is unchanged. The 35 novel synthetic portion of pNN01 is shown in Figure 4.

by the Church-Gilbert approach, of the ends of an inserted fragment using NotI digestion and four 20-nucleotide long probes: NN-A, NN-B, NN-C and NN-D. See Figure 5.

5 Two sequencing results of significance were obtained directly from our subclones by the Church-Gilbert method. In one experiment, we probed PvuII digested DNA from  $\lambda$ HT16 independently with LF10 and LF11 (Figure 5) to determine the sequence across 10 the EcoRI sites bounding the 224 bp EcoRI fragment. This directly refuted the possibility that the analysis of the two EcoRI subclones (pHT16H and pHT16L) of this phage had overlooked sequences either 15 5' to the small EcoRI fragment or between the two EcoRI fragments. We also confirmed this result by analysis of the NotI subcloned pP26, which has this EcoRI site intact. We also digested pP26 with PvuII and sequenced the fragment by the Church-Gilbert method using LF10 (Figure 5) as hybridization probe. 20 This proved that the 5' terminus of the insert of was exactly the same as that of  $\lambda$ HT16.

Figure 3 shows the DNA sequence of the cDNA insert of phage  $\lambda$ HT16. It also depicts the DNA sequence coding for LFA-3 and the amino acid sequence deduced therefrom. This latter cDNA, e.g., that 25 coding for LFA-3, contained DNA sequences coding for the amino acid sequences that we had determined for the N-terminal region and the 4 tryptic fragments of LFA-3 purified from human erythrocytes.

30 Expression of LFA-3 HT16 cDNA in CHO cells

960 bp NcoI-MaeI fragment of p24HT16LFA3#8 described below is inserted into the SmaI site of BG312 expression vector to give BG8 expression vector. Vector BG8 has been deposited with In Vitro International Culture Collection, 611 P. Hammonds 35 Ferry Rd., Linthicum, Maryland, 21090 on May 24,

1988 and has been assigned accession number IVI-10170. In the BG312 (Cate et al., Cell, 45, p.685 (1986)) the expression of the inserted DNA sequence is under the control of the Adenovirus 2 late promoter.

5 p24HT16LFA3#8 was constructed by ligating a 800 bp EcoRI fragment of pHT16 with the large EcoRI fragment of p24, containing the plasmid portion. The DNA sequence of the EcoRI fragment of p24 corresponds to the DNA sequence of the base pairs 1-223 of figure 3.

10 To establish a stable HT16-CHO cell line, we cotransfected  $1 \times 10^7$  CHO (DHFR<sup>-</sup>) cells (Chasin and Urlaub, Proc. Natl. Acad. Sci., 77, p. 4216 (1980)) with 180  $\mu$ g of XmnI linearized BG8 DNA, 20  $\mu$ g of StuI linearized pAdD26 DNA (Kaufman and Sharp, Mol. Cell. Biol., 2, p. 1304 (1982)) and 200  $\mu$ g of sonicated salmon sperm DNA carrier by electroporation using a BIORAD (Richmond, California) gene pulser at 0.29 UV with capacitance set at 960  $\mu$ FD. We next plated the electroporated CHO cells in non-selective alpha+ (modified

15 Eagle Medium (MEM) for 3 days, then changed to alpha-MEM medium for 4 days at a cell density of  $1 \times 10^5$  cells per 100mm plate. Cells were then grown in alpha- MEM plus either 200 nM, 400 nM or 600 nM methotrexate. Colonies grew best in 200 nM methotrexate,

20 from which we isolated individual clones, grew them to  $1 \times 10^6$  cells per 100 mm plate in order to assay for expression of LFA-3 by measuring the intensity of indirect immunofluorescence on a Fluorescence Activated Cell Sorter (FACS) (Becton Dickinson,

25 Mountainview, California) and for rosetting (cell adhesion) as described below.

To analyze by FACS,  $1 \times 10^6$  cells per each HT16-CHO methotrexate clone and control CHO cells were removed from the tissue culture dishes by incubation with Hank's BSS (spell out) buffer, .5 M EDTA at 4°C for 15 minutes. The detached cells were then

pelleted, resuspended in 50  $\mu$ l of PBN buffer (1 x PBS, .5% BSA, .1% sodium azide) and incubated with 100  $\mu$ l of monoclonal antibody TS2/9 (1.2 mg/ml) (a gift of Tim Springer) on ice for 45 minutes. We 5 next washed the cells two times with 1 ml PBN buffer and pelleted by centrifugation. The cell pellets were resuspended in 100 $\mu$ l of a 1:50 dilution of FCI (Fluorescein Conjugated Affinity Purified F (ab') 2 10 Fragment Sheep Anti-Mouse IgG (Cappel, Biomedical, Pennsylvania)) in PBN buffer and incubated on ice for 30 minutes. Cells were pelleted by centrifugation and excess FCI was removed by resuspending the cell pellets twice in 1 ml PBN (spell out) buffer. We then resuspended the cells in 800  $\mu$ l of 1 x PBS. 15 and determined the fluorescence intensity on FACS. Five clones showed higher fluorescence than control CHO cells and a homogeneous cell population with respect to LFA-3 expression.

We next tested whether the recombinant 20 LFA-3 expressed in CHO cells could adhere to CD2 expressing cells by rosetting analysis. We grew control CHO cells and CHO cells expressing LFA-3 (HT16-CHO #30) in a 9.6  $\text{cm}^2$  well of a 6 well tissue culture plate at a cell density of  $3 \times 10^5$  cells per 25 well. After washing the wells twice with Roswell Park Memorial Institute (RPMI 1060) medium to remove cell debris and dead cells,  $3 \times 10^7$  Jurkatt cells (a gift of Tim Springer) were added per well. Plates were spun at 400 rpm for 2 min. in a Sorvall 30 Centrifuge at 4°C. After the cells were incubated at 4°C for 2 hours the wells were washed with RPMI 1060 medium to remove excess Jurkatt cells. Jurkatt cells rosetted with the LFA-3 expressing HT16-CHO #30 cells as determined under the microscope.

35 We compared the level of surface expression of LFA-3 in HT16-CHO #30 with the expression levels of JY B lymphoblastoid cells (a gift of Tim Springer)

by comparing the relative fluorescence intensities of both cell lines using FACS analysis as described above, using  $2.5 \times 10^6$  JY cells, CHO cells and HT16-CHO #30 cells. HT16-CHO cells showed a 6 fold  
5 higher fluorescence intensity than JY cells.

Expression of LFA-3 HT16 cDNA in R1.1 Cells

$2.6 \times 10^7$  R1.1 cells were cotransfected with 90  $\mu$ g NruI linearized expression vector BG8 as described above, 10 $\mu$ g NruI linearized plasmid pTCF  
10 DNA (F. Grosveld et al. Nucleic Acid Res., 10, p. 6715 (1982) and 300  $\mu$ g sonicated salmon sperm DNA by electroporation (280 volts, 960  $\mu$ FD) as described above. After selecting transfected cells in RPMI 1060 plus 1mg/ml G418, we isolated clones by dilution to  $10^3$  cells per well, in a 96 well microtiter  
15 plate, containing 200  $\mu$ l RPMI 1060 medium plus 1 mg/ml G418. Eight resistant clones were propagated and assayed for LFA-3 surface expression by FACS analysis as described above. We found all eight  
20 HT16-R1.1 clones expressed LFA-3 at levels approximately 25 fold above R1.1 controls, but all showed heterogeneous cell populations with regard to LFA-3 expression.

We further sorted two clones--#13 and #15--  
25 for high expression on FACS.  $1 \times 10^6$  HT16-R1.1 cells of each clone were incubated with 100  $\mu$ l TS2/9 Mab for 45 minutes on ice in PBN buffer (1x PBS, 0.5% BSA, 0.1% sodium azide). After pelleting the cells we washed them twice by resuspending in 1 ml PBN  
30 buffer and resuspended the cell pellet in 100  $\mu$ l of a 1:50 dilution of FCI. After 30 minutes on ice, the cells were washed and resuspended in 800  $\mu$ l 1 x PBS. The surface expression of LFA-3 in the sorted homogeneous population of HT16-R1.1 #13 and #15 is  
35 10% of that on JY cells.

We next tested whether LFA-3 from HT16 cDNA as expressed in R1.1 cells would adhere to other cells by rosetting with L-cells expressing CD2 cDNA (L114) (a gift of Catherine Hession) and with Jurkatt cells (a gift of Tim Springer) using the same method as described above for HT16-CHO. We observed rosetting. This rosetting could be inhibited with Mab to LFA-3 (TS2/9) or Mab to CD2 (TS2/18) (a gift of Tim Springer). This indicated that LFA-3 is expressed on the cell surface of R1.1 cells in a conformation that allows interaction with naturally expressed CD2 receptor on Jurkatt cells or with CD2 expressed on mouse L-cells. HT16-R1.1 cells or untransfected R1.1 cells do not rosette with untransfected mouse L-cells, indicating the specificity of these cellular interactions.

Expression of LFA-3 HT16 cDNA in L-Cells

We cotransfected  $1 \times 10^7$  L (tk-) cells (C. P. Terhorst, J. Immun., 131, p. 2032 (1983)) with 90  $\mu$ g of XmnI linearized BG8 plasmid DNA described above, 10  $\mu$ g ScaI linearized pOPF plasmid DNA (Grosveld et al., supra) (a plasmid carrying the thymidine kinase gene which can be used to select transfected cells), and 300 $\mu$ g sonicated salmon sperm DNA by electroporation as described above. After washing and transferring the cells to 100mm petri dishes we grew them in nonselective medium (DMEM) for 48-72 hours. The transfected cells were then selected for in DMEM + hypoxanthine aminopterine thymidine (HAT) at a cell density of  $1 \times 10^5$  cells per 100 mm dish. We picked 13 clones expressing thymidine kinase after 14 days and expanded them to  $1 \times 10^6$  per 100 mm plate and assayed for LFA-3 expression by FACS analysis as described above. Eleven HT16-L clones showed a 10 to 20 fold higher surface fluorescence than control CHO cells.

We also assayed HT16-L clones for LFA-3 surface expression by immunofluorescence visualized directly under a fluorescence microscope. We found four clones -- HT16L #73, 1, 7, and 27 -- were highly 5 fluorescent, indicating high levels of LFA-3 expression. We next sorted all four clones for high expressing cells on the FACS as described above because these clones showed heterogeneous cell 10 populations of LFA-3 expression. Six clones -- HT16-L #1A, 1B, 1C, 7, 27, and 107 -- selected in HAT-DMEM medium were assayed for LFA-3 expression by 15 FACS analysis. We found all clones showed fluorescence intensities of 20 to 30 fold over that of control CHO cells, except for clone HT16-L-1C which was 35 fold higher.

We also tested whether LFA-3 from HT16 cDNA as expressed in L-cells would adhere to other cells using the same rosetting assay described above for LFA-3 expressed in R1.1 cells. We observed 20 rosetting.

#### Expression of LFA-3 in E.coli

To express LFA-3 cDNA in E.coli, the expression vector pLFA3trcl was constructed. This 25 vector (a derivative of pKK233-2) expresses the mature LFA-3 protein. The DNA sequence of HT16 cDNA coding for the signal sequence was deleted. To construct pLFA3trcl, plasmid pKK233-2 (E. Aman and J. Brofius Gene, 40 p. 183 (1985)) was digested with restriction enzymes NcoI and HindIII, and ligated to 30 an isolated 700 base pair Ava2/Hind3 fragment of pLFA3HT16 and a double stranded linker LF21-22. This linker replaces the sequence between base pairs 101 to 175 (to Ava2 site) of HT16 cDNA (Table I).

Table I

LF21:

5' CATGTTTCCAAACAAATATGGTGTGTATGGAAATG  
TAACCTTCATGT ACCAAGCAATGTGCCTT  
5 AAAAGAG 3' 79 mer

LF22:

5' GACCTTTAAAGGCACATTGCTGGTACATGGAAAGTT  
ACATTCCCATAACACACCATAATTGTT  
GGGAAAAA 3' 78 mer

10 We transformed JA221 cells with the resulting recombinant expression vector. E. coli transformed with pLFA3trcl were grown to  $OD_{550}$  1.0, followed by inducing with 1mM IPTG for 2 hours and collecting the cells by centrifugation. Cells were 15 resuspended in LB and an equivalent of 0.2  $OD_{550}$  was removed. We next pelleted by centrifugation, resuspended the cell pellet in 50 ul SDS-gel loading buffer and boiled for 3 minutes. 25 ul of the 20 sample was loaded onto a SDS-denaturing polyacrylamide gel in order to separate the proteins by electrophoresis. To detect LFA-3, proteins were electrotransferred onto a nitrocellulose membrane, followed by incubating the membrane with a 1:1000 dilution of an antibody to h-LFA-3, K64 (a gift of 25 Tim Springer). We observed that the anti-LFA-3 (K64) antibodies detected a 25 kd protein, indicating that the transformed cells expressed LFA-3.

Cells were next grown in 1 l LB + 50  $\mu$ g/ml 30 ampicillin at 37°C to  $OD_{550}$  0.1. Expression of LFA-3 was induced with 2 mM IPTG for 2 hours. Cells were pelleted at 4000 rpm/4°C for 30 minutes. We resuspended the pellets in 25 mM Tris (pH 7.0) at 1 gm cell pellet per 10 ml Tris buffer and lysed in a French Pressure Cell Press at cell pressure

12,000-14,000 psi. Membrane fractions were next separated from soluble proteins by centrifugation in SS34 Sorvall at 10,000 rpm for 30 minutes at 4°C. Membrane pellets were resuspended in 1 ml of 25 mM Tris pH 7.0. 1  $\mu$ l aliquots of the supernatant and of the membrane pellets were electrophoresed on a 15% SDS-denaturing PAG. The membrane pellets were dissolved in SDS buffer and the proteins were separated by SDS-PAGE, coomassie stained and the LFA-3 excised from the gel for subsequent protein sequencing. Our amino acid sequencing confirmed the N-terminal sequence as M F S Q Q I Y G V V Y G N V T-LFA-3 and F S Q Q I Y G V V Y G N V T-LFA-3 which matches the N-terminal sequence determined for the human LFA-3 purified from human erythrocytes (Wallner, et al. *J. Exp. Med.*, 166:923 (1987)). Accordingly, the product produced by this construction has a N-terminal with and without methionine.

We also modified the DNA sequence encoding LFA-3 to delete from it portions of the hydrophobic transmembrane domain to obtain high levels of expression of soluble forms of LFA-3. We used our LFA-3 cDNA from pHT16 as depicted in Figure 3 which codes for LFA-3 containing a transmembrane domain.

25 LFA-3ML7 Deletion

50  $\mu$ g of plasmid pHT16LFA3 DNA was digested with 100 units of the restriction enzyme ScaI for 1 hour at 37°C. We separated the linearized plasmid from the uncut plasmid by electrophoresis on a 1% agarose gel, excised it from the gel and electroeluted. Another aliquot of 50  $\mu$ g of pHT16LFA3 plasmid DNA was digested with 100 units of EcoRI and 100 units of Hind III for 1 hour at 37°C to excise most of the LFA-3 cDNA sequences in this plasmid. The vector was next separated from the EcoRI/HdIII fragment by

electrophoresis on a 1% agarose gel, excised and electroeluted.

We used an oligonucleotide LF17, to introduce the deletion. This is a 43 mer (depicted in Table II) corresponding to 21 nucleotides, starting at base pairs 632 and 22 nucleotides starting at position 764 base pairs of the HT16 cDNA sequence depicted in Figure 3.

Table II

10	LF16:	3' TAGGGTTCGTCGCCAGTAAGTTACTTACCAAGACTTTACA 5'	42 mer
15	LF17:	3' TAGGGTTCGTCGCCAGTAAGTTAACTAACCAATTGTCTTCTAC 5'	43 mer
20	LF23:	5' TCATCTTCTGTTACCAATCATCTGTGTCTTGAATGACCGCT 3'	41 mer
25	LF28:	5' CAGGGCCCGCCCCGCGTCGCTCCCAGCAAC 3'	30 mer

When this oligonucleotide is hybridized to single-stranded HT16 cDNA, it will loop out 111 base pairs of the HT16 cDNA. 20 pmoles of the electroeluted ScaI and 20 pmoles of the EcoRI/HindIII fragments were mixed with 20 pmoles of phosphorylated LF17, followed by denaturing in 100 mM NaCl, 6 mM Tris (pH 7.6) and 8 mM MgCl<sub>2</sub> at 90°C for 5 minutes and renaturing by incubation at 37°C for 1 hour, at 4°C for 1 hour, and on ice for 10 minutes. To one half of the reaction mix, we added 0.5 µl T4 ligase, 1 mM ATP, 1 µl Klenow and 5 mM of NTP, and the mixture was incubated at 15°C overnight. One half of the reaction mix was transformed into MCL061 competent cells. Colonies containing deleted LFA-3 cDNA were identified by hybridization to LF17, as follows. Transformed MCL061 colonies were transferred to nitrocellulose filters, lysed and the DNA denatured by

treatment with 0.5 N NaOH. The nitrocellulose filters were hybridized in PSB containing  $1 \times 10^5$  cpm/ml  $^{32}\text{P}$ -kinased oligonucleotide LF17 at 65°C overnight. Filters were washed at 65°C in 0.1 x SSC (.015M sodium chloride, .0015 M sodium citrate) and exposed to X-ray film. Positive colonies were picked and grown at 37°C, and lysed. We next prepared DNA (see, Maniatis et al., "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor (1982)). To verify the correct deletion, DNA was digested with EcoRI and Hind III. Four pLFA3M17 colonies had the correct restriction pattern. The correct DNA sequence of one clone was confirmed by DNA sequencing using the method of Maxam and Gilbert (supra).

15 LFA-3M16

Plasmid pLFA3M16-2-4H was constructed essentially as described for LFA3M17, except that the oligonucleotide LF16 (Table II) was used to introduce the deletion. LF16 is a 42 mer of which 21 nucleotides are homologous to base pairs 632 to 652 (Figure 3) and 21 nucleotides to base pairs 716 to 736 (Figure 3) of HT16 cDNA. Mutagenesis with oligonucleotide LF16 deleted the 63 base pair sequence coding for the hydrophobic potential transmembrane domain of LFA-3, leaving the cytoplasmic domain intact. We isolated plasmid pLFA3M16, and verified its correct sequence as described above.

LFA-3M23

Plasmid pLFA3M23 was constructed by procedures described for pLFA3M17. The oligonucleotide used for the mutagenesis was LF23 (Table II), a 41 mer of which twenty-one nucleotides are homologous to base pairs 641 to 661 (Figure 3) and 20 nucleotides to base pairs 767 to 786 (Figure 3) of HT16 cDNA.

Mutagenesis with LF23 deleted the potential trans-membrane and cytoplasmic domain of HT16-LFA-3 cDNA.

We next inserted all deleted LFA-3 cDNAs into expression vectors that also carry a selective marker. We believe having the selective marker on the same plasmid in close proximity to the LFA-3 gene during integration will assure cointegration of these two genes and, therefore, their coselection. We used the expression vector pJOD-s. Vector pJOD-s has been deposited with In Vitro International, Inc. Culture Collection in Linthicum, Maryland, on May 26, 1988, and has been assigned accession number IVI-10171. For the construction of LFA-3M17, M16 and M23, the pJOD-s vector was linearized with restriction enzyme SalI, blunt-ended with Klenow and ligated with the Klenow-blunt ended NotI fragment of pLFA3M17, pLFA3M16 or pLFA3M23. The respective ligation mixtures were next transformed into MC1061, and colonies containing the respective DNA were selected by hybridization to oligonucleotide probe LF28 (see Table II), a 30 mer, homologous to base pairs 20 to 49 of HT16 cDNA at 65°C in PSB and washed at 0.5 x SSC (0.75M NaCl, 0.075M NaCl) at 65°C. Positive colonies were picked, grown overnight in LB + amp 50 µg/ml, and DNA prepared. The correct sizes of the inserts were verified by restriction enzyme mapping. Four clones of pLFA3M17, three clones of pLFA3M16 and one clone of pLFA3M23 showed the correct restriction enzyme patterns. DNA was prepared from a clone of pLFA3M17, pLFA3M16 and pLFA3M23, and the correct DNA sequences were confirmed by DNA sequencing using the method of Maxam and Gilbert (supra).

To establish stable CHO cell lines, 10 µg of pLFA3M17 that had been linearized with PvulI was transfected into CHO cells by the calcium phosphate procedure and electroporation as described above.

The same procedure is used for establishing stable CHO cell lines with pLFA3M16 and pLFA3M23.

CHO cells transfected with pLFA3M17 were assayed for secretion of soluble LFA-3 by metabolic labeling with <sup>35</sup>S methionine. 5x10<sup>5</sup> cells per well of a 6 well plate were labeled with <sup>35</sup>S methionine for 18 hours and <sup>35</sup>S-LFA-3 precipitated with Mab TS2/9. We observed that M17/CHO secreted LFA-3. It should be understood that to obtain higher expression, M17/CHO may be amplified in high concentrations of methotrexate to amplify the LFA-3 gene.

To enable further the above-described invention, we deposited the following phage carrying an LFA-3 DNA sequence of this invention in the In Vitro International, Inc. Culture Collection in Linthicum, Maryland, on May 28, 1987:

λHT16 [λgt10/LFA-3]

The phage has been assigned accession number IVI 10133.

While we have herein before presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which we have presented by way of example.

CLAIMS:

1. A DNA sequence selected from the group consisting of:

(a) the DNA insert carried in phage  $\lambda$ HT16;

(b) DNA sequences which hybridize under conditions equivalent to about 20° to 27°C below  $T_m$  to the above DNA insert and which code on expression for a polypeptide that binds to CD2, the receptor on the surface of T-lymphocytes; and

(c) DNA sequences which code on expression for a polypeptide coded for on expression by any of the foregoing DNA sequences or inserts.

2. The DNA sequence according to claim 1, wherein said DNA sequence (b) codes on expression for a polypeptide that binds to CD2 on the surface of T-lymphocytes and inhibits adhesion between T-lymphocytes and target cells.

3. The DNA sequence according to claim 2, wherein said polypeptide is soluble.

4. The DNA sequence according to claim 1, wherein said DNA sequence is selected from the group consisting of a DNA sequence of the formula  $N_{1-1047}$  of Figure 3, a DNA sequence of the formula  $N_{17-766}$  of Figure 3, a DNA sequence of the formula  $N_{101-766}$  of Figure 3, a DNA sequence of the formula  $N_{101-611-N_{716-766}}$  of Figure 3, a DNA sequence of the formula  $ATG-N_{101-766}$  of Figure 3, a DNA sequence of the formula  $ATG-N_{101-661-N_{716-766}}$  of Figure 3, a DNA sequence of the formula  $N_{1-652-N_{716-1047}}$  of Figure 3, and DNA sequence of the formula  $N_{1-652-N_{764-1047}}$  of Figure 3, a DNA sequence of the formula  $N_{1-661-N_{764-1047}}$  of Figure 3.

1047 and DNA sequences that code on expression for any of the above DNA sequences.

5. The DNA sequence according to claim 4, wherein said DNA sequence is selected from the group consisting of a DNA sequence of the formula  $N_{17-766}$  of Figure 3, a DNA sequence of the formula ATG- $N_{17-766}$  of Figure 3, and DNA sequences that code on expression for any of the above DNA sequences.

6. A recombinant DNA molecule comprising a DNA sequence selected from the group consisting of the DNA sequences of claims 1 to 5, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule.

7. The recombinant DNA molecule according to claim 6, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase and the promoters of the yeast  $\alpha$ -mating factors.

8. The recombinant DNA molecule according to claim 6, wherein the molecule is selected from the group consisting of pLFA3trcl, BG8, pLFA3M16, pLFA3M17 and pLFA3M23.

9. A unicellular host transformed with a recombinant DNA molecule selected from the group consisting of the recombinant DNA molecules of claims 6, 7 or 8.

10. The host according to claim 9, wherein said host is selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi, animal cells, plant cells and human cells in tissue culture.

11. The unicellular host according to claim 10, wherein the animal cell is selected from the group consisting of CHO, R1.1 and L-M(tK<sup>-</sup>).

12. A polypeptide coded on expression by a DNA sequence selected from the group consisting of the DNA sequences of claims 1 to 5, said polypeptide being essentially free of other proteins of human origin.

13. The polypeptide according to claim 12, wherein said polypeptide is selected from the group consisting of a polypeptide of the formula AA<sub>-22</sub>-AA<sub>222</sub> of Figure 3, a polypeptide of the formula AA<sub>1-222</sub> of Figure 3, a polypeptide of the formula Met-AA<sub>1-222</sub> of Figure 3, a polypeptide of the formula AA<sub>1-187</sub>-AA<sub>206-222</sub> of Figure 3, a polypeptide of the formula AA<sub>-28-184</sub>-AA<sub>206-222</sub> of Figure 3, a polypeptide of the formula AA<sub>1-184</sub>-AA<sub>206-222</sub> of Figure 3, a polypeptide of the formula AA<sub>-28-184</sub> of Figure 3, a polypeptide of the formula AA<sub>1-184</sub> of Figure 3, a polypeptide of the formula AA<sub>-28-187</sub> of Figure 3, and a polypeptide of the formula AA<sub>1-187</sub> of Figure 3.

14. A method of producing a polypeptide comprising the steps of culturing a unicellular host according to claim 9.

15. The method according to claim 14 wherein the transformed host is selected from the group consisting of CHO(BG8), R1.1(BG8) L-M(tK<sup>-</sup>)

(BG8) E.coli JA221 (pLFA3trcl) CHO(pLFA3M16),  
CHO(pLFA3M17) and CHO(pLFA3M23).

16. A pharmaceutical composition comprising an immunosuppressant or enhancement effective amount of a polypeptide selected from the group consisting of the polypeptides of claim 12 or 13 and a pharmaceutically acceptable carrier.

17. A method of treating patients comprising the step of treating them in a pharmaceutically acceptable manner with a composition selected from the group consisting of the compositions of claim 16.

18. A diagnostic composition to detect T-cell subsets, CD2+ cells or to monitor the course of diseases characterized by excess or depleted T-cells comprising a diagnostic effective amount of a polypeptide selected from the group consisting of the polypeptides of claim 12 or 13 or an antibody thereto.

19. A method of detecting T-cell subsets, CD2+ cells or for monitoring the course of diseases characterized by excess or depleted T-cells comprising the step of employing as a diagnostic a composition selected from the group consisting of the compositions of claim 18.

20. A means for detecting T-cell subsets, CD2+ cells or for monitoring the course of diseases characterized by excess or depleted T-cells comprising a composition selected from the group consisting of the compositions of claim 18.

## FIG. I

NH<sub>2</sub> Terminus : 150-? FSQQIYGVVYGVXTFHVPSNVP  
LKEVLWKKQKDVKAEI

T <sub>72-73</sub>	:	DKVAELENSEF
T <sub>91</sub>	:	VYLDTVSGSLTIVNLTS
T <sub>105</sub>	:	FFLYVLESLPSPLTLCAL
T <sub>68</sub>	:	GLIMYS

FIG. 4

## FIG. 2

Oligonucleotide Probe Pool LF1:  
20mer, 32fold degenerate

Corresponds to amino acid sequence:

trp lys lys gln lys asp lys  
 5'— TGG AAA AAA CAG AAA GAC AAA  
           G    G    A    G    T    G

Probe Sequence:

3'           ACC TTT TTT GTC TTT CTG TT  
               C    C    T    C    A

Oligonucleotide Probe Pool LF2-5:  
20mer 384fold degenerate. Synthesized in four subpools of  
96fold degeneracy.

Correspond to amino acid sequence:

gln gln ile tyr gly val val  
 5'           CAG CAG ATC TAC GGN GTN GTN  
               A    A    T    T  
                  A

Probe Sequence:

3'           GTC GTC TAG ATG CCN CAN CA  
               T    T    A    A  
                  T  
 LF2:   3'   GTC GTC TAG ATG CCA CAN CA  
               T    T    A    A  
                  T  
 LF3:   3'   GTC GTC TAG ATG CCT CAN CA  
               T    T    A    A  
                  T  
 LF4:   3'   GTC GTC TAG ATG CCG CAN CA  
               T    T    A    A  
                  T  
 LF5:   3'   GTC GTC TAG ATG CCC CAN CA  
               T    T    A    A  
                  T

FIG. 3A

DNA Sequence and Amino Acid Sequence of Human LFA3

FIG. 3B

NOT TO BE TAKEN INTO  
CONSIDERATION FOR THE  
PURPOSES OF INTERNATIONAL  
PROCESSING (See Section 310(d)(ii)  
OF THE ADMINISTRATIVE INSTRUCTIONS)

## ANNEX M3

International Application No: PCT/US88/01924

## MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 33, line 17 of the description.<sup>1</sup>A. IDENTIFICATION OF DEPOSIT<sup>2</sup>Further deposits are identified on an additional sheet  <sup>3</sup>Name of depositary institution<sup>4</sup>

In Vitro International, Inc.

Address of depositary institution (including postal code and country)<sup>4</sup>611 P. Hammonds Ferry Road  
Linthicum, Maryland 21090Date of deposit<sup>5</sup>

May 28, 1987

Accession Number<sup>6</sup>

1V1 10133

B. ADDITIONAL INDICATIONS<sup>7</sup> (leave blank if not applicable). This information is continued on a separate attached sheet 

"In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4)EPC)"

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE<sup>8</sup> (If the indications are not for all designated States)D. SEPARATE FURNISHING OF INDICATIONS<sup>9</sup> (leave blank if not applicable)The indications listed below will be submitted to the International Bureau later<sup>10</sup> (Specify the general nature of the indications e.g. "Accession Number of Deposit")E.  This sheet was received with the International application when filed (to be checked by the receiving Office)

(Authorized Officer)

 The date of receipt (from the applicant) by the International Bureau <sup>11</sup>

22 NOV 1988

1985)

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/01924

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) <sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(4): C12P 21/00 C12N 5/00 C12N 1/00

US. CL. 435/68, 240.2 320

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System	Classification Symbols
U.S.	435/68, 70, 91, 172.3, 243, 253, 254, 240.2, 320 935/11,12, 15, 27, 36, 70, 71 530/350 536/27

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>

Chemical Abstract Database (CAS) 1967-1988 BIOSIS DATA BASE 1969-1988  
Keywords: LFAB, CDZ, T cells, cloning mRNA

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y, P	U.S., a, 4,738,927 (TANIGUCHI ET AL.), 19 April 1988. See abstract, background examples 1-4.	1-20
X, P	J. of Exper. Med., Vol. 166, issued 1987 Oct. (Amsterdam, Netherlands), (Wallner et al.), Primary Structure of Lymphocyte function associated antigen 3 (LFA-3) See pgs 923-931.	1-15
X	J. of Exp. Med., Vol. 165, issued 1987 March (Amsterdam, Netherlands), (Dustin et al), Purified Lymphocyte Function Associated Anigen 3 binds to CD2 and mediates T lymphocyte adhesion see pgs. 677-692.	6-8, 12-13 and 18-20

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

18 August 1988

Date of Mailing of this International Search Report

07 OCT 1988

International Searching Authority

ISA/US

Signature of Authorized Officer

Patricia Carson

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	<u>Proc. Natl. Acad. Sci.</u> , Vol. 83, issued Nov 1986, (Washington, D.C.) Molecular "Cloning of the human T-lymphocyte surface CD2(T11) antigen" see pgs 8718-8722, see particularly page 8719.	1-11
X,P	<u>J. of Exper. Med.</u> , Vol. 166, issued Oct. 1987, (Amsterdam, Netherlands), (Selvaraj et al.), "Deficiency of Lymphocyte Function Associated Antigen 3 (LFA3) in Paroxysmal Nocturnal Hemoglobinuria" see pages 1011-1025. see particularly pages 1011,1012.	16-20
Y	<u>Proc. Natl. Acad. Sci.</u> Vol. 79 issued Dec. 1982 (Washington, D.C.), (Sanchez-Madrid et al), "Three distinct antigens associated with human T-lymphocytes mediated cytolysis LFA-1, LFA-2, LFA-3" pages 7489-7493.	1-13
X,P	<u>Nature</u> , Vol. 329, issued 29 Oct. 1987 (Tokyo, Japan), (SEED), "An LFA-3 cDNA encodes a phospholipid linked membrane protein homologous to its receptor CD2" pages 840-844.	1-15
A	<u>Proc. Natl. Acad. Aci.</u> Vol. 81, issued Jan, 1984 (Washington, D.C.) "Immunoprecipitation of cell surface structures of cloned cytotoxic T lymphocytes by clone specific antisera pages 573-577.	
Y	<u>J. of Immunology</u> , Vol. 138, 1 June 1987 (Washington, D.C.), (Makgoba et al.) "Human T cell Rosetting is mediated by LFA3 on erythrocytes" pages 3587-3589.	18-20

Attachment to PCT/ISA/210  
Part VI.

Group I: Claims 1-15 drawn to DNA sequences, vectors, host cells, polypeptide and a method of making the polypeptide.

Group II: Claims 16-17 drawn to a pharmaceutical composition and a method of treating patients.

Group III: Claims 18-20 drawn to a diagnostic composition and a method of use.